The agreement expands Evotec’s drug discovery platform into the area of respiratory diseases through IR Pharma’s expertise in in vitro and in vivo Respiratory pharmacology.
Under the alliance, Evotec will provide fully integrated respiratory and inflammation focused drug discovery programmes to its partners, from target to nomination of pre-clinical development candidates.
Evotec chief operating officer Mario Polywka said IR Pharma is an expertise in the respiratory disease area and they hope can bring outstanding value to existing and future partners and collaborators in these demanding disease areas.
Financial details of the agreement have not been disclosed.